Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 2c

Karyopharm Reports Third Quarter 2015 Financial Results and Highlights Recent Progress

November 9, 2015 7:30 AM EST

Robust Recruitment and New Study Initiations Continue

Additional Encouraging Data on Selinexor in Combination with Other Active Agents to be Presented at ASH

Conference Call Scheduled for Today at 8:30 a.m. ET

NEWTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2015 and commented on recent accomplishments and clinical development plans for its pipeline of SINE-based therapeutics including selinexor, its lead product candidate.

"This has been a very busy... More